About Us

“Our purpose is to combine the strengths of British academia, research and industry in life sciences and provide expertise in the development of new businesses in biologics. We bring British science to business.”

ImmunoSYS stems from a strong immunology research background and is specialised in immunologic mechanisms that are translational in therapeutic (drugs) safety assessment. Our innovative platform in immune response analysis brings new and much needed solutions to the drug market. This is our key focus area.

On a more general level, ImmunoSYS is a Manchester based biological company providing solutions to biological businesses through academia-to-industry translation of bioscience. Our target sectors are biopharma and agri-business. Our areas of interest are immunology, proteins,  bio-analysis, probiotics, biomarkers, recombinants, microbes, mammalian biology, helminths, and veterinary vaccines.

ImmunoSYS works in transferring British technology to biopharma and agri-business industries in progressive overseas markets such as in Asia, impacting supply chain and feedback to the UK and EU markets. We also partner with European biotech companies bringing advanced methods and products in molecular and cellular biology to the UK biopharma industry.



We engage in three ways:


Capacity build-up for research and manufacture of biologics – generally in the form of large-scale long-term projects with clients. These usually continue onto follow-on research and trade partnerships. Clients of this group belong to manufacturers in the pharmaceuticals or agribusiness industries who want to attain the ability to develop, manufacture and analyse products of biological origins.


  • Providing an Ultra-Sensitive-Assay and Microdosing service to research and drug discovery groups.
  • Providing preclinical immune response analysis for the immunogenic safety assessment of new drugs
  • Modelling to understand the biomolecular properties of drugs. Models are of two categories – (i) immune modelling, and (ii) mathematical modelling.


Performing research on biomolecular, immunologic and cellular aspects in collaboration with academic and/or industrial partners with the aim to make immunologic research more translational. Research outcomes will be products that can be commercialised. Projects can be funded by UK or EU grant bodies.


Targeting growth markets: Asia and the CEE

ImmunoSYS puts a lot of importance in growth markets such as Asia and Central and Eastern Europe (CEE). These markets are extremely important for the global economy in terms of food security, medicine and energy. By helping to create a standardised and dependable infrastructure for research and manufacture in these progressive regions through knowledge transfer and generating new product lines, we are creating a feedback system for the British and European biological industry. This will increase trade of biologics and impact the overall supply chain.


The Manchester Heritage

Manchester is the world’s first industrial city where the industrial revolution took place during Victorian Britain. With the birth of molecular physics and chemistry through the works of Dalton, Rutherford, Bohr and Chadwick, or the world’s first stored-program electronic digital computer (the ‘Baby’) in 1948, or the largest steerable dish radio telescope (‘Jodrell Bank Observatory’) in the world in the 50s and many more scientific episodes Manchester has given the modern world milestone leaps. Many discoveries have brought Nobel recognition to Manchester and through the years Manchester has grown tremendously in biomolecular research. Today Manchester along with other clusters in the North West is a leader in inflammation and disease mechanisms, tissue engineering and cancer studies. ImmunoSYS is an independent company closely linked with scientists working at the University of Manchester and also other top research institutes in the UK bringing the best of British life sciences. We make British academic research more transferable and translated. Essentially, we are working to bridge the gap between British academia and industry, also in tune with EU growth strategies.